Clinical trials, such as the Assessment of the Effects of Efpeglenatide on Cardiovascular and Renal Outcomes (AMPLITUDE-O) trial, have demonstrated that GLP-1 RAs reduce the incidence of macroalbuminuria in patients with DKD, independent of glycemic control (101). Here, GLP1R is linked to diabetic kidney disease.